AVTX — Avalo Therapeutics Share News
0.000.00%
Last trade - 00:00- $399.54m
- $1.27m
- $0.06m
Brief: Avalo Therapeutics Enters Milestone Buyout Option Agreement On April 26 - SEC Filing
Avalo Therapeutics posts lower-than-expected 2025 net loss
Brief: Avalo Therapeutics Files For Mixed Shelf Of Up To $750 Million - SEC Filing
U.S. RESEARCH ROUNDUP- Autozone, Coursera, Lennar
Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete
Brief: Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa
Avalo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Avalo Therapeutics Inc expected to post a loss of $1.62 a share - Earnings Preview
Brief: Avalo Therapeutics Enters $75 Million Sales Agreement With TD Cowen For Common Stock Offering
Avalo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Avalo Therapeutics Inc expected to post a loss of $1.39 a share - Earnings Preview
Brief: Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board
U.S. RESEARCH ROUNDUP-Finance of America Companies, SM Energy, Verizon
U.S. RESEARCH ROUNDUP-Blue Owl Capital, Insulet, Unity Software
Avalo Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Avalo Reports Third Quarter 2024 Financial Results And Recent Business Updates
Brief: Avalo Therapeutics Regains Compliance With Nasdaq Listing Rule
Brief: BVF Partners Reports 9.99% Passive Stake In Avalo Therapeutics Inc As Of Aug 13
Brief: RA Capital Management Reports 9.99% Passive Stake In Avalo Therapeutics Inc As Of Aug 13